Rome Therapeutics was founded to develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome.
The repeatome makes up 60% of our genome and consists of repetitive sequences of nucleic acids, known as repeats. These repeats have long been dismissed as “junk DNA.” Much of this region is thought to derive from viruses that embedded in our DNA millions of years ago. In healthy cells, DNA of the repeatome is tightly packed and silent. But when cells are stressed or sick, during circumstances like an infection, cancer or autoimmune disease, this repetitive DNA can unfold, causing the cell to transcribe it into RNA.
Rome believes that medicines targeting the repeatome could revolutionize the way many diseases are treated. The company has already picked out several targets to pursue in cancer and autoimmune disease and is working towards generating small molecule modulators of these targets. Multiple other discovery programs are underway.
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® …
ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung …
Alchemab identifies naturally occurring protective antibodies that counter complex diseases, such as cancer and neurodegenerative diseases, by mining the antibody repertoires of individuals who are …
Israel-based Wild Biotech is mining wild animal microbiomes for the discovery of novel human therapeutics, based on the “largest database ever assembled of the microbiome …
MUVON Therapeutics is spin-off from the University of Zurich developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or …
Founded in 2020, Chimerna Therapeutics has developed a platform for generating circular RNA, which overcomes the major limitations of RNA therapeutics, namely stability and abundance. …
